QED Program Call for Submissions; Science Center Seeks Academic Technologies with Commercial Potential
The University City Science Center is seeking proposals for its QED Proof-of-Concept Program. Academic researchers with technologies ripe for commercialization, and who are affiliated with the 21 partner academic and research institutions in Pennsylvania, New Jersey and Delaware, are encouraged to submit proposals. QED, now in its tenth round, is the first multi-institutional proof-of-concept program for the life sciences and healthcare IT. The program provides academic researchers with mentoring, business advice, and in some cases, funding to commercialize their early-stage technologies.
Connect to compete: Philadelphia’s University City-Center City innovation district
Philadelphia’s innovation economy is strong, but city leaders can do more with its existing assets to compete globally and benefit local communities, according to a new report from the Anne T. and Robert M. Bass Initiative on Innovation and Placemaking at the Brookings Institution.
Report: University City’s tech scene can explode with growth and help nearby neighborhoods
A new report from the nonprofit Brookings Institution examines Philly’s burgeoning tech scenes against those in other cities, and suggests the city should invest in education and medicine — particularly in University City’s Innovation District.
Study calls for University City, W. Center City ‘Innovation District’
Philadelphia needs a coherent planning vision to solidify University City and western Center City into a financial and knowledge hub that can help the city prosper, scholars with the Brookings Institution, a Washington think tank, said in a report to be released Thursday.
Enterin’s RASMET study enrolls first patient with Parkinson’s Disease
Enterin, Inc. a CNS pharmaceutical company based in Philadelphia and developing novel compounds to treat Parkinson’s disease (PD) has enrolled the first patient in the RASMET study. The study is a Phase 1/2a randomized, controlled multi-center study involving patients with PD and taking place at 12 US sites. It will enroll 50 patients over a 9-12 month period. The first Stage is open label and involves single escalating doses in 10 patients with PD. Participating sites include Denver, Boca Raton, Tampa and Cleveland. Details relating to the study can be found at ClinicalTrials.gov. and contact information is available on Enterin’s website, www.enterininc.com.
Intermountain makes strides in precision medicine, advanced imaging
Intermountain HealthCare is making strides on two critical fronts in healthcare: precision genomics and advanced imaging technology. The Salt-Lake City-based health system announced Thursday the Intermountain Precision Genomics service would offer genomic sequencing of solid tumors, a new genomic test for cancer. An adjunct to the ICG100 Comprehensive Cancer panel, which tests 162 genes, the ICG100 ONCO Focus Panel requires less DNA.
Rachel Cervantes Joins University City Science Center as VP Corporate Development
Rachel Cervantes, Ph.D., MBA has joined the University City Science Center as VP Corporate Development. Cervantes brings over 20 years’ experience in the commercial and scientific aspects of pharmaceutical innovation within large pharmaceutical, biotech, and academic research environments.